If you would like to submit a blog post for consideration, please email email@example.com
Can a course of fluorouracil cream reduce a person’s risk of BCC and SCC?
This month’s paper from JAMA Dermatology, by Weinstock et al, is instructive. The authors did a randomised trial of five per cent fluorouracil cream applied to the face, to see if a two to four week application would reduce the number of basal cell carcinomas (BCC) and squamous cell carcinomas (SCC) in the following year.
Interestingly, there was a significant and important reduction of 75 per cent in the number of SCC that developed. There was no corresponding reduction in BCC. The benefit did not persist over the four year study.
There are some interesting implications and considerations we can take from this. The study was done in a high risk group, and presumably by treating SCC precursors (such as actinic keratosis) the five per cent fluorouracil has a beneficial effect – but only for a year.
So, as the authors note, maybe an annual course of fluorouracil is justified in high risk patients.
Professor David Wilkinson.
Read more from Professor David Wilkinson on recent research:
- A New Way to Evaluate Acral Lesions
- How is artificial intelligence changing skin cancer medicine?
- Proportion of Melanomas Managed by GPs in Australia
- Mohz Micrographic Surgery vs. Wide Local Excision for Melanoma In Situ
- Treating Melanoma in Primary Care
Interested in skin cancer medicine?
The HealthCert Professional Diploma programs offer foundation to advanced training in skin cancer medicine, skin cancer surgery or dermoscopy and provide an essential step towards subspecialisation. All programs are university quality-assured, CPD-accredited and count towards multiple Master degree pathways and clinical attachment programs in Australia and overseas. The programs are delivered online and/or face-to-face across most major cities of Australia.